What is Interius BioTherapeutics?
Founded in 2021, Interius BioTherapeutics is an early-stage biotechnology enterprise dedicated to expanding the therapeutic potential of cell and gene medicine. The company leverages groundbreaking inventions originating from the laboratory of Dr. Saar Gill at the University of Pennsylvania. Its core mission centers on the development of innovative delivery technologies designed to overcome current limitations in gene therapy administration. By focusing on precision and efficacy, Interius aims to address significant unmet medical needs, establishing a unique market position within the rapidly evolving life sciences ecosystem.
How much funding has Interius BioTherapeutics raised?
Interius BioTherapeutics has raised a total of $76M across 1 funding round:
Series A
$76M
Series A (2021): $76M with participation from Cormorant Asset Management, Fairmount Funds Management, and Bain Capital
Key Investors in Interius BioTherapeutics
Cormorant Asset Management
A prominent life sciences investment firm with over $3B in assets under management, focusing on fundamental scientific principles to support innovative biotech companies.
Fairmount Funds Management
A Philadelphia-based investment firm specializing in supporting innovative therapies and groundbreaking technologies within the biotechnology and life science sectors.
Bain Capital
A leading global private investment firm that applies deep sector expertise and broad capabilities to provide flexible capital solutions and strategic value-add services.
What's next for Interius BioTherapeutics?
With the recent infusion of capital, Interius BioTherapeutics is poised to scale its operational capabilities and advance its lead candidates through the preclinical pipeline. The company's strategic roadmap emphasizes the refinement of its delivery platform, which is essential for the successful translation of its scientific discoveries into viable clinical applications. As the firm continues to build its internal expertise and infrastructure, it remains focused on achieving key milestones that will validate its technology and attract further institutional interest. The current funding environment suggests a strong trajectory for the company as it navigates the complexities of drug development and seeks to establish long-term value in the global healthcare market.
See full Interius BioTherapeutics company page
